Opinion|Videos|July 15, 2024

Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies

Author(s)Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center

An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.

Episodes in this series

EP. 1 Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning

EP. 1 Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning

EP. 2 Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

EP. 2 Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

EP. 3 Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies

EP. 3 Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies

EP. 4 Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population

EP. 4 Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population

EP. 5 Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

EP. 5 Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

EP. 6 Panel Discuses Use of CD19 Bispecifics in Sequencing

EP. 6 Panel Discuses Use of CD19 Bispecifics in Sequencing

EP. 7 Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion

EP. 7 Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion

EP. 8 Current Approach to Bridging Therapy in R/R DLBCL

EP. 8 Current Approach to Bridging Therapy in R/R DLBCL

EP. 9 Risk of Secondary Malignancies in Heavily Pre-Treated Population

EP. 9 Risk of Secondary Malignancies in Heavily Pre-Treated Population

EP. 10 Management of CRS and ICANS with CAR T-cell Therapy

EP. 10 Management of CRS and ICANS with CAR T-cell Therapy

EP. 11 Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line

EP. 11 Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line

EP. 12 Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy

EP. 12 Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy

EP. 13 Bispecific therapy – treatment setting and management of short-term adverse events

EP. 13 Bispecific therapy – treatment setting and management of short-term adverse events

EP. 14 Bispecific therapy – management of long-term adverse events in the community setting

EP. 14 Bispecific therapy – management of long-term adverse events in the community setting

EP. 15 Practice Patterns and Real Use of Epcoritamab and Glofitamab

EP. 15 Practice Patterns and Real Use of Epcoritamab and Glofitamab

EP. 16 Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

EP. 16 Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

Video content above is prompted by the following:

Please discuss the data supporting CAR T-cell therapy as the primary 2Ltreatment option for patients who are transplant-eligible and have primary refractory or early relapse R/R DLBCL.
- Please review the latest 56-month follow-up data of the ZUMA-7study, evaluating axi-cel.
  - ASH 2024 Update: Subgroup Analysis of the ZUMA-7 study.
  - Please discuss the subsequent cellular immunotherapy off-protocol in the SOC arm.
Please review the 36-month follow-up data of the TRANSFORM study, evaluating liso-cel.
- ASCO 2024 Update: Subgroup analysis of the TRANSFORM study [primary refractory vs. early relapsed].
What were some key takeaways from the results of these two studies?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Melanoma | Image Credit: © Pter - stock.adobe.com

November 6th, 2026

Adjuvant Intismeran Autogene Plus Pembrolizumab Data Headline Key Melanoma Findings From ESMO 2026

Experts break down key melanoma data and trends from the 2026 ESMO Congress.

News Quiz

November 6th, 2026

OncLive Weekly News Quiz (11/6/2026): Did You Miss Crucial Hematologic, Lung, and Desmoid Tumor Updates?

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

RCC | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

November 6th, 2026

LITESPARK-012, XmAb819, and PE-PE Data Headline Key Kidney Cancer Findings From ESMO 2026

Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.

maya2008 - stock.adobe.com

November 5th, 2026

BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC

Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.

FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC

November 5th, 2026

FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC

The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.

UCLA | Image Credit © peterschreiber.media - stock.adobe.com

November 5th, 2026

Routine Breast Imaging May Offer Little Benefit After Double Mastectomy for Early Breast Cancer

A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.

Gynecologic Cancers | Image Credit: © Crystal light - stock.adobe.com

November 5th, 2026

TroFuse-005, KEYNOTE-C93, and ADC Data Headline Key Gynecologic Cancer Findings from ESMO 2026

Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.

Maurie Markman, MD

November 5th, 2026

Palliative and Supportive Care: Time for Recognition of Critical Relevance

Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?

Trending on OncLive

FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC

BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC

Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Routine Breast Imaging May Offer Little Benefit After Double Mastectomy for Early Breast Cancer